Skip to content

Kernicterus Due To Isoimmunization C0270204

Published: July 22, 2026Updated: August 25, 2026

Brain damage from severe jaundice in newborns, often due to blood type incompatibility. Early treatment of jaundice can help prevent this serious complication.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 25, 2026Editorial policy

Key facts at a glance

ICD-10
G43.909
ICD-11
8A00.0
Body system
neurologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Acute bilirubin encephalopathy (lethargy, hypotonia, poor feeding)

Generalized symptoms

(neurologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Sensorineural hearing loss

(neurologic)

Athetoid cerebral palsy (choreoathetosis)

(neurologic)

Dental enamel hypoplasia

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Exchange Transfusion

Blood exchange procedure that removes bilirubin-laden blood and replaces it with donor blood. This is the most effective method for rapidly reducing serum bilirubin levels in severe cases to prevent further neurological damage.

procedure
2

Targeted drug therapy with dose adjustment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Intensive Phototherapy

High-intensity blue light therapy that converts bilirubin into water-soluble forms for excretion. Used in conjunction with exchange transfusion for severe cases or as primary treatment for moderate elevation.

procedure

Additional treatment options

Intravenous Immunoglobulin (IVIG)

Immunomodulatory therapy that may reduce hemolysis in isoimmune conditions. Typically administered when hemolysis is ongoing despite other interventions.

medication

Bilirubin Level Surveillance

Regular monitoring of serum bilirubin levels through laboratory testing to assess treatment response and guide further interventions. May require frequent measurements in acute phase.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Kernicterus Due To Isoimmunization C0270204?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Kernicterus Due To Isoimmunization C0270204. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy